Tags

Type your tag names separated by a space and hit enter

The complexity of tau in Alzheimer's disease.
Neurosci Lett. 2019 07 13; 705:183-194.NL

Abstract

Alzheimer's disease (AD) is characterized by two major pathological lesions in the brain, amyloid plaques and neurofibrillary tangles (NFTs) composed mainly of amyloid-β (Aβ) peptides and hyperphosphorylated tau, respectively. Although accumulation of toxic Aβ species in the brain has been proposed as one of the important early events in AD, continued lack of success of clinical trials based on Aβ-targeting drugs has triggered the field to seek out alternative disease mechanisms and related therapeutic strategies. One of the new approaches is to uncover novel roles of pathological tau during disease progression. This review will primarily focus on recent advances in understanding the contributions of tau to AD.

Links

PMC Free PDF

Authors+Show Affiliations

Naseri NN
Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, USA. Electronic address: nin2006@med.cornell.edu.
Wang H
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA.
Guo J
The University of North Carolina at Chapel Hill, Chapel Hill, USA.
Sharma M
Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, USA.
Luo W
Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, USA. Electronic address: wel2009@med.cornell.edu.

MeSH

Alzheimer DiseaseHumansInflammationSynaptic Transmissiontau Proteins

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

31028844

Citation

Naseri, Nima N., et al. "The Complexity of Tau in Alzheimer's Disease." Neuroscience Letters, vol. 705, 2019, pp. 183-194.
Naseri NN, Wang H, Guo J, et al. The complexity of tau in Alzheimer's disease. Neurosci Lett. 2019;705:183-194.
Naseri, N. N., Wang, H., Guo, J., Sharma, M., & Luo, W. (2019). The complexity of tau in Alzheimer's disease. Neuroscience Letters, 705, 183-194. https://doi.org/10.1016/j.neulet.2019.04.022
Naseri NN, et al. The Complexity of Tau in Alzheimer's Disease. Neurosci Lett. 2019 07 13;705:183-194. PubMed PMID: 31028844.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The complexity of tau in Alzheimer's disease. AU - Naseri,Nima N, AU - Wang,Hong, AU - Guo,Jennifer, AU - Sharma,Manu, AU - Luo,Wenjie, Y1 - 2019/04/25/ PY - 2018/12/04/received PY - 2019/03/14/revised PY - 2019/04/08/accepted PY - 2019/4/28/pubmed PY - 2019/12/24/medline PY - 2019/4/28/entrez KW - Acetylation KW - Alzheimer's disease KW - Glia KW - Neurodegeneration KW - Neuroinflammation KW - Phosphorylation KW - Synaptic dysfunction KW - Tau KW - Tau aggregation and propagation KW - Tauopathies SP - 183 EP - 194 JF - Neuroscience letters JO - Neurosci Lett VL - 705 N2 - Alzheimer's disease (AD) is characterized by two major pathological lesions in the brain, amyloid plaques and neurofibrillary tangles (NFTs) composed mainly of amyloid-β (Aβ) peptides and hyperphosphorylated tau, respectively. Although accumulation of toxic Aβ species in the brain has been proposed as one of the important early events in AD, continued lack of success of clinical trials based on Aβ-targeting drugs has triggered the field to seek out alternative disease mechanisms and related therapeutic strategies. One of the new approaches is to uncover novel roles of pathological tau during disease progression. This review will primarily focus on recent advances in understanding the contributions of tau to AD. SN - 1872-7972 UR - https://www.unboundmedicine.com/medline/citation/31028844/The_complexity_of_tau_in_Alzheimer's_disease_ DB - PRIME DP - Unbound Medicine ER -